表紙
市場調査レポート

世界の遺伝子検査市場の見通し

Genetic Testing Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 270811
出版日 ページ情報 英文 135 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
世界の遺伝子検査市場の見通し Genetic Testing Market Outlook 2020
出版日: 2015年06月01日 ページ情報: 英文 135 Pages
概要

世界の遺伝子検査市場は、2014年〜2020年のCAGRで、10%の成長が見込まれています。

当レポートでは、世界の遺伝子検査市場について調査分析し、市場情勢に焦点を当てて、促進要因、新興部門、規制の枠組みについて検証し、遺伝子検査の応用、企業リストなども含め、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 遺伝子検査の概要

  • 応用と利点
  • 手法

第4章 世界の遺伝子検査市場の概要

  • 市場の見通し
  • 遺伝子検査研究所:アンメットニーズ分析
  • DTC式遺伝子検査

第5章 促進要因と課題

  • 促進要因
  • 課題

第6章 疾患別分析

  • アルツハイマー病
  • 嚢胞性線維症
  • ブルーム症候群

第7章 国別分析

  • 米国
  • 欧州
  • アジア太平洋地域

第8章 新興部門

  • 次世代シークエンシング (NGS)
  • 非侵襲性出生前診断 (NIPD)
  • 癌の全ゲノムシークエンシング (WGS)
  • 個別化医療

第9章 遺伝子検査の規制

第10章 競合評価

  • Abbott Laboratories
  • Roche Diagnostics
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific
  • Agilent Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Qiagen NV
  • Cepheid
  • Affymetrix, Inc.

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The term ‘Genetic Testing’ refers to tests performed on DNA and RNA samples collected from patients. The so called ‘predictive tests’ give scientists and medical professionals vital clues to how an individual may develop a disease. These innovative tests can assess the risk of onset of a specific disease (genetic) based on the mutated genetic code even before the disease is symptomatic. Today, Genetic Testing is entitled as one of the fastest evolving segments of the molecular diagnostics market. Supported by factors such as growing incidences of chronic diseases, surging awareness for chromosomal abnormalities among pregnant women, and intensive R&D expenditures, the market for genetic testing is showing an impressive growth worldwide.

RNCOS’ analysts have predicted that the Global Genetic Testing market will grow at a CAGR of 10% during the forecasted period 2014-2020. The new edition of the report “Genetic Testing Market Outlook 2020”, highlights the market landscape, key contributing drivers of the market, emerging sectors, and the regulatory framework surrounding the genetic testing segment. The report is an outcome of an in-depth market analysis by our team of analysts. It also covers the application aspect of genetic tests in several therapeutic areas, as well as the list of genetic tests available in the market.

The research effectively illustrates the growth of Genetic Testing in both developed and developing countries. There is a comprehensive analytics too of key developments in major markets including the US, Europe and Asian countries. A country level analysis depicts the level of penetration of genetic testing, types of tests available, consumer perspectives, and future growth.

Key vendors influencing the industry include Abbott, Roche, Siemens, Illumina, Thermo Fischer Scientific, and Myriad Genetics among others. The report analyzes a competitive landscape of the market by properly analyzing the business, services and activities of the companies along with their SWOT analysis. Overall, the latest edition provides a comprehensive overview of the global genetic testing market, which will enable clients and investors to frame a successful business strategy to enter the Billion dollar industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Genetic Testing Overview

  • 3.1. Application and Advantages
  • 3.2. Methods

4. Global Genetic Testing Market Overview

  • 4.1. Market Outlook
  • 4.2. Genetic Testing Laboratories - Unmet Need Analysis
  • 4.3. Direct-to-Consumer (DTC) Genetic Testing

5. Drivers & Challenges

  • 5.1. Drivers
    • 5.1.1. Increasing Public Awareness for Genetic Tests
    • 5.1.2. Rising Incidence of Chronic Diseases
    • 5.1.3. Growth in Ageing Population
  • 5.2. Challenges
    • 5.2.1. Decline in Fertility Rates
    • 5.2.2. Ethical and Policy Issues

6. Disease-Wise Analysis

  • 6.1. Alzheimer's Disease
  • 6.2. Cystic Fibrosis
  • 6.3. Cancer
  • 6.4. Bloom Syndrome

7. Country-Level Analysis

  • 7.1. US
    • 7.1.1. Market Overview
    • 7.1.2. Recent Developments
  • 7.2. Europe
    • 7.2.1. Market Overview
    • 7.2.2. Recent Developments
  • 7.3. Asia-Pacific
    • 7.3.1. Market Overview
    • 7.3.2. Recent Developments

8. Emerging Sectors

  • 8.1. Next-Generation Sequencing (NGS)
  • 8.2. Non-Invasive Prenatal Testing (NIPT)
  • 8.3. Whole Genome Sequencing (WGS) for Cancer
  • 8.4. Personalized Medicine

9. Genetic Testing Regulation

10. Competitive Assessment

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Product Offering
    • 10.1.3. Key Financials
    • 10.1.4. Recent Developments
    • 10.1.5. Strengths & Weaknesses
  • 10.2. Roche Diagnostics
    • 10.2.1. Company Overview
    • 10.2.2. Product Offering
    • 10.2.3. Key Financials
    • 10.2.4. Recent Developments
    • 10.2.5. Strengths & Weaknesses
  • 10.3. Myriad Genetics, Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Product Offering
    • 10.3.3. Key Financials
    • 10.3.4. Recent Developments
    • 10.3.5. Strengths & Weaknesses
  • 10.4. Thermo Fisher Scientific
    • 10.4.1. Company Overview
    • 10.4.2. Product Offering
    • 10.4.3. Key Financials
    • 10.4.4. Recent Developments
    • 10.4.5. Strengths & Weaknesses
  • 10.5. Agilent Technologies Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Product Offering
    • 10.5.3. Key Financials
    • 10.5.4. Recent Development
    • 10.5.5. Strengths & Weaknesses
  • 10.6. Hologic, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Product Offering
    • 10.6.3. Key Financials
    • 10.6.4. Recent Developments
    • 10.6.5. Strengths & Weaknesses
  • 10.7. Illumina, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Product Offering
    • 10.7.3. Key Financials
    • 10.7.4. Recent Developments
    • 10.7.5. Strengths & Weaknesses
  • 10.8. Qiagen NV
    • 10.8.1. Company Overview
    • 10.8.2. Product Offering
    • 10.8.3. Key Financials
    • 10.8.4. Recent Developments
    • 10.8.5. Strengths and Weaknesses
  • 10.9. Cepheid
    • 10.9.1. Company Overview
    • 10.9.2. Product Offering
    • 10.9.3. Key Financials
    • 10.9.4. Recent Developments
    • 10.9.5. Strengths and Weaknesses
  • 10.10. Affymetrix, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Product Offering
    • 10.10.3. Key Financials
    • 10.10.4. Recent Developments
    • 10.10.5. Strength and Weaknesses

List of Figures:

  • Figure 4-1: Genetic Testing Market (Billion US$), 2014-2020
  • Figure 4-2: Genetic Testing Market by Geography (%), 2014
  • Figure 4-3: Genetic Testing Market by Geography (%), 2020
  • Figure 7-1: Number of Disorders, Genes, Labs, & Clinics for Genetic Testing (2014 & 2015)
  • Figure 7-2: Number of Genetic Tests Performed (2013-2015)
  • Figure 7-3: US - Genetic Testing Market (Billion US$), 2014-2020
  • Figure 7-4: Europe - Genetic Testing Market (Billion US$), 2014-2020
  • Figure 7-5: Asia-Pacific - Genetic Testing Market (Million US$), 2014-2020
  • Figure 8-1: Global - Next Generation Sequencing Market (Billion US$), 2014-2020
  • Figure 8-2: Global - NGS Application by Sector (%)
  • Figure 8-3: Global - Next Generation Sequencing Market by Player (%), 2013
  • Figure 8-4: Global - Non-Invasive Prenatal Testing Market (Million US$), 2014-2020
  • Figure 8-5: US - Tapped and Untapped Personalized Cancer WGS Market (%), 2013
  • Figure 8-6: US - Personalized Cancer WGS Market (Million US$), 2014-2020
  • Figure 8-7: Organizational Transformation to Support Personalized Medicine
  • Figure 9-1: Genetic Testing Regulatory Agencies
  • Figure 10-1: Abbott Laboratories - Revenue Breakup by Segments (%), 2014
  • Figure 10-2: Abbott Laboratories - Revenue Breakup by Geography (%), 2014
  • Figure 10-3: Roche Holding - Revenue Breakup by Segments (%), 2014
  • Figure 10-4: Roche Holding - Diagnostic Division Revenue by Geography (%), 2014
  • Figure 10-5: Myriad Genetics - Revenue Breakup by Segments (%), 2014
  • Figure 10-6: Life Technologies - Revenue Breakup by Segments (%), 2014
  • Figure 10-7: Life Technologies - Revenue Breakup by Geography (%), 2014
  • Figure 10-8: Agilent - Revenue Breakup by Segments (%), 2014
  • Figure 10-9: Hologic - Revenue Breakup by Segments (%), 2014
  • Figure 10-10: Hologic - Revenue Breakup by Geography (%), 2014
  • Figure 10-11: Illumina - Revenue Breakup by Geography (%), 2014
  • Figure 10-12: Qiagen NV - Revenue Break up by Segments (%), 2014
  • Figure 10-13: Qiagen NV - Revenue Break up by Geography (%), 2014
  • Figure 10-14: Cepheid - Revenue Break up by Segments (%), 2014
  • Figure 10-15: Cepheid - Revenue Break up by Geography (%), 2014
  • Figure 10-16: Affymetrix - Revenue Breakup by Segments (%), 2014
  • Figure 10-17: Affymetrix - Revenue Breakup by Geography (%), 2014

List of Tables:

  • Table 4-1: Key DTC Genetic Testing Companies by Category
  • Table 4-2: Key Test Areas Offered in DTC Genetic Testing Segment
  • Table 7-1: FDA Approved Pharmacogenomic Biomarkers for Oncology
  • Table 9-1: Abbott Laboratories - Key Gene Based Products
  • Table 9-2: Abbott Laboratories - Financial Performance (Million US$), 2012-2014
  • Table 9-3: Roche Molecular Diagnostics - Key Gene Based Products
  • Table 9-4: Roche Holding - Financial Performance (Million US$), 2012-2014
  • Table 9-5: Myriad Genetics - Key Gene Based Products
  • Table 9-6: Myriad Genetics - Financial Performance (Million US$), 2012-2014
  • Table 9-7: Life Technologies - Key Gene Based Products
  • Table 9-8: Life Technologies - Financial Performance (Million US$), 2012-2014
  • Table 9-9: Agilent - Key Gene Based Products
  • Table 9-10: Agilent - Financial Performance (Million US$), 2012-2014
  • Table 9-11: Hologic - Key Gene Based Products
  • Table 9-12: Hologic - Financial Performance (Million US$), 2012-2014
  • Table 9-13: Illumina - Key Gene Based Products
  • Table 9-14: Illumina - Financial Performance (Million US$), 2012-2014
  • Table 9-15: Qiagen NV - Key Gene Based Products
  • Table 9-16: Qiagen NV - Financial Performance (Million US$), 2012-2014
  • Table 9-17: Cepheid - Key Gene Based Products
  • Table 9-18: Cepheid - Financial Performance (Million US$), 2012-2014
  • Table 9-19: Affymetrix - Key Gene Based Products
  • Table 9-20: Affymetrix - Financial Performance (Million US$), 2012-2014
Back to Top